Effect of the Platelet-Rich Plasma(PRP) injection in primary manifestations of knee osteoarthritis

Effect of the Platelet-Rich Plasma (PRP) injection in primary manifestations of knee osteoarthritis in patients who refer to rheumatology clinic of Kowsar hospital, Semnan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015010112823N2

Enrollment

Registered

2015-01-19

Start date

2014-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary manifestations of osteoarthritis. M17

Interventions

Intervention 1: In the first group (N=30) 3 CC autologous PRP by a syringe which covered in aluminum foil will be intraarticularly injected. The patient is not aware of the contents of the syringe (re

Treatment - Drugs

In the first group (N=30) 3 CC autologous PRP by a syringe which covered in aluminum foil will be intraarticularly injected. The patient is not aware of the contents of the syringe (real injections).

For patients in the control group (n=30) an empty syringe which covered by aluminum foil prepared and its needle enter up to 5 mm into skin and fat tissue without entering into the joint space (Pseudo

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- age 40-60 years, 2- a history of chronic knee pain for at least 12 months, 3-Kellgren-Lawrence radiological criteria for having developing osteoarthritis of the knee (grade 1 and 2). Exclusion criteria: 1. Thrombocytopenia, 2- taking anticoagulant agents during the past 2 weeks 3- taking immunosuppressive drugs, NSAIDs and corticosteroids, 4- liver or renal disease, 5- leukemia and lymphoma, 6- a history of malignancy, active malignant disease, 7- severe cardiovascular disease including congestive heart failure, myocardial infarction and cardiac arrhythmia, 8- bacterial arthritis at least during last 6 months, 9- intra-articular injection of steroid or hyaluronic acid during the last 6 months, 10- use of cigarettes and tobacco 11- fever and systemic infections and local infection in injection site.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Befor and 3 and 6 months after intervention. Method of measurement: IKDC, EQ-VAS and Tegner criteria.	—

Secondary

Measure	Time frame
Physical Activities. Timepoint: 6 months after intervantion. Method of measurement: IKDC? EQ-VAS and Tegner criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Jamileh Moghimi

Semnan University of Medical Sciences

moghimi_jam@yahoo.com+98 23 3345 1336

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026